Menu
Recruiting NCT07632742

Moses 2.0 vs Magneto for HoLEP - a Randomized Controlled Trial

No phase Interventional Enlarged Prostate (BPH) Benign Prostatic Hyperplasia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Magneto 150 holmium laser, Moses 2.0 holmium laser.
Who it may be relevant to
Registry conditions: Enlarged Prostate (BPH), Benign Prostatic Hyperplasia. Basic parameters: 18 years — 100 years · Male.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

MOSES 2.0 vs Quanta Magneto 150 Holmium Laser for Holmium Laser Enucleation of the prostate-a Randomized Controlled Trial

Overview

The objective of this study is to compare the Magneto 150 holmium laser to the current MOSES 2.0 technology to see if there is a benefit in decreased hemostasis time intraoperatively.

Detailed description

The Magneto 150 is a high-powered 150W holmium laser that offers similar pulse-modulation benefits of MOSES 2.0, which facilitates effective dissection and enucleation of the tissue plane while also offering a new first-of-its kind proprietary Magneto setting which allows for very low peak power of 500W and longer pulse duration which allows for better hemostasis.

Interventions

  • Device Magneto 150 holmium laser
    The HoLEP procedure will be performed using the Quanta Magneto 150 holmium laser
  • Device Moses 2.0 holmium laser
    The HoLEP procedure will be performed using the Moses 2.0 holmium laser

Primary outcome measures

  • Mean hemostasis time [Time frame: During surgery]
Secondary outcome measures (3)
  • Mean (average) enucleation time [Time frame: During surgery]
  • Total operative time [Time frame: During surgery]
  • Hemostasis efficiency [Time frame: During surgery]

Eligibility criteria

Inclusion criteria

  • Undergoing HoLEP for the treatment of bothersome lower urinary tract symptoms
  • Internet access and a device to complete postoperative questionnaires (smartphone, tablet, laptop or desktop computer)

Exclusion criteria

  • Patients who lack decisional capacity
  • Patients unable to read/speak English
  • Patients who are on a blood thinner (anticoagulation medication)
  • Patients who do not have internet access to complete postoperative surveys

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 1 center
  • Northwestern University — Chicago

Identifiers

NCT: NCT07632742 · STU00225001

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗